Android app Apple app link

Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE)

By Yahoo! Finance   |   1 month ago
Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE)

Apogee Therapeutics (NASDAQ: APGE) is a hot stock to invest in, with a Buy rating and $89 price target. Positive results from its APEX study on drug APG777 for treating atopic dermatitis have boosted its potential.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.